The ATOS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATOS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ATOS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ATOS Detailed Price Forecast - CNN Money||View ATOS Detailed Summary - Google Finance|
|View ATOS Detailed Summary - Yahoo! Finance||View ATOS Stock Research & Analysis - Zacks.com|
|View ATOS Trends & Analysis - Trade-Ideas||View ATOS Major Holders - Barrons|
|View ATOS Call Transcripts - NASDAQ||View ATOS Breaking News & Analysis - Seeking Alpha|
|View ATOS Annual Report - CompanySpotlight.com||View ATOS OTC Short Report - OTCShortReport.com|
|View ATOS Fundamentals - TradeKing||View ATOS SEC Filings - Bar Chart|
|View Historical Prices for ATOS - The WSJ||View Performance/Total Return for ATOS - Morningstar|
|View the Analyst Estimates for ATOS - MarketWatch||View the Earnings History for ATOS - CNBC|
|View the ATOS Earnings - StockMarketWatch||View ATOS Buy or Sell Recommendations - MacroAxis|
|View the ATOS Bullish Patterns - American Bulls||View ATOS Short Pain Metrics - ShortPainBot.com|
|View ATOS Stock Mentions - StockTwits||View ATOS Stock Mentions - PennyStockTweets|
|View ATOS Stock Mentions - Twitter||View ATOS Investment Forum News - Investor Hub|
|View ATOS Stock Mentions - Yahoo! Message Board||View ATOS Stock Mentions - Seeking Alpha|
|View Insider Transactions for ATOS - SECform4.com||View Insider Transactions for ATOS - Insider Cow|
|View ATOS Major Holdings Summary - CNBC||View Insider Disclosure for ATOS - OTC Markets|
|View Insider Transactions for ATOS - Yahoo! Finance||View Institutional Holdings for ATOS - NASDAQ|
|View ATOS Stock Insight & Charts - FinViz.com||View ATOS Investment Charts - StockCharts.com|
|View ATOS Stock Overview & Charts - BarChart||View ATOS User Generated Charts - Trading View|
Atossa Genetics Announces Receipt of $10 Million
Posted on Monday March 18, 2019
Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that on March 14 and 15, 2019, it received approximately $10 million from exercises of previously outstanding warrants. “The $10 million in cash proceeds significantly enhances our cash position and provides working capital for our ongoing and planned clinical studies,” commented Kyle Guse, CFO and General Counsel of Atossa Genetics.
What Type Of Shareholder Owns Atossa Genetics Inc.’s (NASDAQ:ATOS)?
Posted on Thursday March 14, 2019
Every investor in Atossa Genetics Inc. (NASDAQ:ATOS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insidersRead More...
Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing
Posted on Thursday March 14, 2019
Atossa Genetics news about it getting approval from the U.S. Food and Drug Administration (FDA) for one its its drugs has its stock soaring.Source: Shutterstock Atossa Genetics (NASDAQ:ATOS) has announced that its breast cancer drug Endoxifen has been given special approval by the FDA. This approval is for using the drug to treat a specific patient under the organization's expanded access program.This Atossa Genetics news has the company using Endoxifen as a "post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient." This same patient also took part in a three-week course of the drug prior to her surgery.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Here's what Dr. Steven C. Quay, President and CEO of Atossa Genetics, has to say about the news."We are extremely pleased that this patient not only benefitted from Endoxifen prior to her surgery, but that the FDA agrees that continued Endoxifen therapy is appropriate for this pre-menopausal patient. This positive progress supports our expansion of oral Endoxifen clinical trials. After surgery is completed, the current standard of care in the USA to prevent a recurrence and/or a new cancer is for patients to undergo ovarian ablation (chemical treatment to induce menopause) and take aromatase inhibitors (AI) for 5 to 10 years. Alternatively, tamoxifen therapy can be used for 5-10 years for those patients who do not want to take AIs, or for whom these medications are contraindicated. This patient, like many others, was not a good candidate for tamoxifen therapy due to low liver enzyme (CYP2D6) activity which means her liver would not adequately metabolize tamoxifen. Unlike tamoxifen, oral Endoxifen does not require liver metabolism so it may be a better treatment approach."ATO stock was up 249% as of noon Thursday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing appeared first on InvestorPlace.
Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. This patient completed a 3-week course of Atossa’s oral Endoxifen prior to her surgery under an FDA-approved expanded access program. The tumor activity from the initial biopsy was compared to the tumor activity at surgery, finding that the cancer cell biological activity was reduced by two measures: the Ki-67 activity decreased by 50 percent, and the estrogen receptor content decreased by over 20 percent.